ZELSUVMI's 17% QoQ revenue growth and 25% unit growth confirm the commercial trajectory is intact, but the stock already reflects this momentum (92% analyst bullish). The narrowing loss is driven partly by a $5.2M non-cash gain from convertible debt fair value change, not operational leverage. Watch for Q2 2026 dispensed unit data (April already reported at 3,776) and any early XEPI launch signals. The $32M cash runway supports operations into 2027 but the company remains pre-profitability with rising SG&A.
Price Chart
Executive Summary
Pelthos Therapeutics reported Q1 2026 revenue of $10.9M (product revenue $10.7M, up 17% QoQ from $9.1M) and a GAAP net loss of -$10.2M (-$3.09/share), improving from -$21.7M in Q4 2025. ZELSUVMI commercial momentum continued with 7,884 units dispensed (+25% QoQ) and 3,228 unique prescribers. The company ended Q1 with $32.0M cash and reiterated plans to launch XEPI (early 2027) and XEGLYZE (mid-2027). The sequential revenue growth and narrowing loss are positive, but the company remains pre-profitability with rising SG&A ($21.1M vs $18.5M QoQ) and no formal guidance provided.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $10.9M (product revenue $10.7M, license/collaboration $0.2M)
- ZELSUVMI net product revenue $10.7M, up 17% QoQ from $9.1M in Q4 2025
- 7,884 ZELSUVMI units dispensed in Q1 2026, up 25% from 6,312 in Q4 2025
- 3,228 unique prescribers in Q1 2026, up from 2,377 in Q4 2025
- GAAP net loss -$10.2M (-$3.09/share) vs -$21.7M (-$6.87/share) in Q4 2025
- Adjusted EBITDA -$8.0M vs -$7.6M in Q4 2025
- Cash balance $32.0M at March 31, 2026, up from $18.0M at Dec 31, 2025 (includes $30M term loan draw)
- SG&A expenses $21.1M, up 14% QoQ from $18.5M, driven by sales force expansion and marketing
- Sales force expanded to 64 territory managers from 50 at end of Q4 2025
- April 2026 dispensed units reached 3,776, with cumulative >20,000 units since July 2025 launch
- XEPI launch expected early 2027; XEGLYZE launch expected mid-2027
- No formal financial guidance provided for Q2 2026 or full year 2026
Financial Impact
Q1 2026 revenue $10.9M vs consensus $10.4M (beat); GAAP EPS -$3.09 vs consensus -$4.00 (beat). Sequential revenue growth of 17% QoQ and narrowing net loss from -$21.7M to -$10.2M.
Risk Factors
- SG&A rising faster than revenue (14% QoQ vs 17% revenue growth) — operating leverage not yet visible
- No formal guidance provided; forward visibility limited to management commentary
- Dependence on ZELSUVMI for near-term revenue; XEPI/XEGLYZE launches not until 2027
- Convertible debt fair value changes create volatility in reported net income
- Competitive risk from alternative molluscum treatments (cantharidin-based products)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001919246-26-000071 |
| Document: pths-20260514.htm | 0001919246-26-000071 |
| Document: investmentdeck_202605x99.htm | 0001919246-26-000071 |
| Document: 0001919246-26-000071-index-headers.html | 0001919246-26-000071 |
| Document: 0001919246-26-000071-index.html | 0001919246-26-000071 |
| Document: 0001919246-26-000071.txt | 0001919246-26-000071 |
| 8-K Data (Synthetic) | 0001919246-26-000071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | 8-K | $20.60 $20.50 | ▼ −0.49% | ▼ −1.65% | $17.01 (−17.43%) |
Aug 13, 2026 10w ago | 8-K | $28.95 $26.66 | ▲ +7.91% | ▲ +5.95% | $17.01 (+41.24%) |
Aug 3, 2026 12w ago | Press Release | $26.84 | awaiting T+5 | — | $17.01 (−36.62%) |
Jun 17, 2026 18w ago | Insider Cluster | $29.00 $29.21 | ▲ +0.72% | ▲ +2.39% | $17.01 (−41.34%) |
May 28, 2026 21w ago | 8-K | $26.47 $25.55 | ▼ −3.48% | ▼ −0.95% | $17.01 (−35.74%) |
May 22, 2026 22w ago | 144 | $26.66 $26.20 | ▼ −1.73% | ▼ −3.40% | $17.01 (−36.20%) |
May 21, 2026 22w ago | 8-K | $26.66 $26.20 | ▲ +1.73% | ▲ +3.38% | $17.01 (+36.20%) |
May 14, 2026 23w ago | 8-K | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
May 14, 2026 23w ago | Press Release | $27.69 $27.10 | ▼ −2.13% | ▼ −1.41% | $17.01 (−38.57%) |
Apr 20, 2026 26w ago | 3 | $23.00 $24.97 | ▲ +8.57% | ▲ +7.48% | $17.01 (−26.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers